Aleksandra Pavlenko

Ms. Aleksandra Pavlenko

G.B. Elyakov Pacific Institute of Bioorganic Chemistry of the Far Eastern Branch of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in Molecules
Verified
Journal Article
Open access
PDF file
AKAleksandra Kvetkina
Aleksandra Kvetkina
OMOlesya Malyarenko
Olesya Malyarenko
APAleksandra Pavlenko
Aleksandra Pavlenko
Sergey DyshlovoySergey Dyshlovoy
Sergey Dyshlovoy
GAGunhild Von Amsberg
Gunhild Von Amsberg
Elena LeychenkoElena Leychenko
Elena Leychenko
Actinoporins are the most abundant group of sea anemone cytolytic toxins. Their membranolytic activity is of high interest for the development of novel anticancer drugs. However, to date the activity of actinoporins in malignant cells has been poorly studied. Here, we report on recombinant analog of Hct-S3 (rHct-S3), belonging to the combinatory library of Heteractis crispa actinoporins. rHct-S3 exhibited cytotoxic activity against breast MDA-MB-231 (IC50 = 7.3 µM), colorectal HT-29 (IC50 = 6.8 µM), and melanoma SK-MEL-28 (IC50 = 8.3 µM) cancer cells. The actinoporin effectively prevented epidermal growth factor -induced neoplastic transformation of JB6 Cl41 cells by 34% ± 0.2 and decreased colony formation of HT-29 cells by 47% ± 0.9, MDA-MB-231 cells by 37% ± 1.2, and SK-MEL-28 cells by 34% ± 3.6. Moreover, rHct-S3 decreased proliferation and suppressed migration of colorectal carcinoma cells by 31% ± 5.0 and 99% ± 6.4, respectively. The potent anti-migratory activity was proposed to mediate by decreased matrix metalloproteinases-2 and -9 expression. In addition, rHct-S3 induced programmed cell death by cleavage of caspase-3 and poly (ADP-ribose) polymerase, as well as regulation of Bax and Bcl-2. Our results indicate rHct-S3 to be a promising anticancer drug with a high anti-migratory potential.

1 December 2024 in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
Verified
Journal Article
Closed access
PDF file
APAleksandra Pavlenko
Aleksandra Pavlenko
AKAnna Klimovich
Anna Klimovich
Ekaterina YurchenkoEkaterina Yurchenko
Ekaterina Yurchenko
AKAleksandra Kvetkina
Aleksandra Kvetkina
Elena LeychenkoElena Leychenko
Elena Leychenko
Malignant tumors represent a serious problem for humanity due to their widespread distribution and severe posttherapeutic consequences. The formation of metastases is the main criterion for tumor malignancy. A search for new compounds with antimetastatic activity remains an urgent problem. In this work, the antitumor activity of a cytolytic toxin Hct-S3 оf the sea anemone Heteractis magnifica was studied in an in vivo model of solid Ehrlich adenocarcinoma. It was established that intraperitoneal administration of Hct-S3 at doses of 0.01 and 0.02 mg/kg has hardly any effect on the tumor growth rate but prevents its metastasis from the primary tumor localization to other tissues. A significant decrease in the proliferative capacity of tumor cells was observed in the groups of mice treated with 0.01 and 0.02 mg/kg Hct-S3: the area of the tumor fluorescence zone decreased by 40 and 48%, and the index of integrated fluorescence density increased by 134 and 146%, respectively, as compared with animals without therapy. The obtained results confirm a high antiproliferative and antimetastatic potential of Hct-S3, which allows it to be considered as a promising compound for creating antitumor drugs.

15 April 2025 in Neuropharmacology
Verified
Journal Article
Closed access
OSOksana Sintsova
Oksana Sintsova
SPSteve Peigneur
Steve Peigneur
RKRimma Kalina
Rimma Kalina
N(Nadezhda Otstavnykh (Chernysheva)
Nadezhda Otstavnykh (Chernysheva)
MGMikhail Garbuz
Mikhail Garbuz
ELElena Leychenko
Elena Leychenko

17 October 2026 in Acta Biomedica Scientifica
Verified
Journal Article
Open access
PDF file
APAleksandra Pavlenko
Aleksandra Pavlenko
AKAleksandra Kvetkina
Aleksandra Kvetkina
SBSergey N. Baldaev
Sergey N. Baldaev
Elena LeychenkoElena Leychenko
Elena Leychenko
АПА. П. Павленко
А. П. Павленко
ЕЛЕ. В. Лейченко
Е. В. Лейченко
The development of new, more effective analgesic drugs with high affinity for biological targets is a critical challenge. The peptide HCRG21, a TRPV1 channel blocker derived from the sea anemone Heteractis magnifica, is considered as a promising candidate for a new analgesic drug. Aim. To investigate the genetic and expression stability of the Escherichia coli strain Origami2(K12)/pLysS/pSMT3_HCRG21, which produces the SMT3_HCRG21 fusion protein. Materials and methods. The viability of the working seed lot (WSL) during sequential passaging was assessed by calculating the cell titer in each passage. The number of generations of WSL cells was determined based on the viable cell titer values for each passage using an appropriate equation. The expression level of the fusion protein during continuous cell passaging was calculated as the ratio of the fusion protein amount to the total cellular protein in the cell lysate. Protein content was determined using the Lowry method and electrophoresis. The size of the DNA region encoding the SMT3_HCRG21 fusion protein was determined by PCR and electrophoretic separation, and Sanger sequencing was performed to confirm its genetic identity as specified in the strain passport. Results. During continuous passaging, the cell titer has been shown to vary from 8.3·10 7 to 1.7·10 9 cells/mL, and the average number of generations was 10.4 ± 2.3. Following pDNA amplification of clones from 10, 90, and 140 generations the PCR fragments of approximately 600 bp in length were obtained, which correspond to the length of the nucleotide sequence of the pSMT3_HCRG21 genetic construct (541 bp). The nucleotide sequences of the obtained PCR fragments were identical to those specified in the strain passport. It was demonstrated that the average content of the fusion protein across generations remained at 16 %, indicating a high stability of the strain productivity level. Conclusions. The biosynthetic activity and viable cell titer of the E. coli strain Origami2(K12)/pLysS/pSMT3_HCRG21 remained stable; therefore, the strain can be used for industrial production of the analgesic peptide HCRG21.